Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Esomeprazole Sodium

FDA-approved product (injectable, intravenous), marketed as Esomeprazole Magnesium, Nexium, Nexium 24hr and 3 more.

Registered studies
46
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Esomeprazole Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Ankylosing spondylitis
  • Duodenal ulcer
  • Esophagitis
  • Gastric ulcer
  • Gastroesophageal reflux disease
  • Osteoarthritis
  • Rheumatoid arthritis
  • Zollinger-Ellison Syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Proton pump inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli43.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis30.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

46registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Esomeprazole Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Esomeprazole Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

    NCT02637557 · start 2016-03-01

    Registered record
    Registry ID
    NCT02637557
    Conditions
    Gastroesophageal Reflux Disease
    Interventions
    IW-3718; Matching Placebo; PPI
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-03-01
    Completion
    2017-04-26
    Enrolment
    282

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroesophageal Reflux Disease
    InterventionIW-3718; Matching Placebo; PPI
    PhasePhase 2
    Registry statusCompleted

  • Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment

    NCT02708355 · start 2016-01

    Registered record
    Registry ID
    NCT02708355
    Conditions
    Heartburn
    Interventions
    Esomeprazole 20 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-01
    Completion
    2016-04
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeartburn
    InterventionEsomeprazole 20 mg; Placebo
    PhasePhase 4
    Registry statusCompleted

  • The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS)Applied on Cardiac Surgery With Cardiopulmonary Bypass

    NCT02479581 · start 2015-07

    Registered record
    Registry ID
    NCT02479581
    Conditions
    Valvular Heart Disease
    Interventions
    ERAS group; ERAS group; ERAS group; ERAS group; ERAS group; ERAS group; ERAS group; ERAS group; ERAS group; ERAS group; ERAS group; ERAS group; Conventional control group; ERAS group; Conventional control group; Conventional control group; Conventional control group; Conventional control group; Conventional control group; Conventional control group
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-07
    Completion
    2017-05
    Enrolment
    226

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionValvular Heart Disease
    InterventionERAS group; ERAS group; ERAS group; ERAS group +16 more
    PhasePhase 2
    Registry statusCompleted

  • BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects

    NCT01964131 · start 2013-10

    Registered record
    Registry ID
    NCT01964131
    Conditions
    Gastric Ulcer; Duodenal Ulcer; Anastomotic Ulcer; Reflux Esophagitis; Etc.
    Interventions
    D961H sachet 20 mg; D961H HPMC capsule 20 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-10
    Completion
    2013-12
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Ulcer; Duodenal Ulcer; Anastomotic Ulcer; Reflux Esophagitis +1 more
    InterventionD961H sachet 20 mg; D961H HPMC capsule 20 mg
    PhasePhase 1
    Registry statusCompleted

  • Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)

    NCT01669811 · start 2012-08

    Registered record
    Registry ID
    NCT01669811
    Conditions
    Refractory Reflux Esophagitis
    Interventions
    Esomeprazole (D961H) twice daily; Esomeprazole (D961H) once daily
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-08
    Completion
    2014-05
    Enrolment
    1,398

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRefractory Reflux Esophagitis
    InterventionEsomeprazole (D961H) twice daily; Esomeprazole (D961H) once daily
    PhasePhase 3
    Registry statusCompleted

  • A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)

    NCT01544114 · start 2012-04

    Registered record
    Registry ID
    NCT01544114
    Conditions
    Juvenile Idiopathic Arthritis (JIA)
    Interventions
    VIMOVO 250/20; VIMOVO 375/20; VIMOVO 500/20
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-04
    Completion
    2015-02
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionJuvenile Idiopathic Arthritis (JIA)
    InterventionVIMOVO 250/20; VIMOVO 375/20; VIMOVO 500/20
    PhasePhase 4
    Registry statusCompleted

  • Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease

    NCT01132638 · start 2011-08

    Registered record
    Registry ID
    NCT01132638
    Conditions
    GERD
    Interventions
    Magnesium Pantoprazole; Magnesium Esomeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-08
    Completion
    2012-06
    Enrolment
    713

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGERD
    InterventionMagnesium Pantoprazole; Magnesium Esomeprazole
    PhasePhase 3
    Registry statusCompleted

  • Efficacy of Esomeprazole in Patients With Frequent Heartburn

    NCT01370525 · start 2011-08

    Registered record
    Registry ID
    NCT01370525
    Conditions
    Heartburn
    Interventions
    Esomeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-08
    Completion
    2011-10
    Enrolment
    340

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeartburn
    InterventionEsomeprazole
    PhasePhase 3
    Registry statusCompleted

  • Efficacy of Esomeprazole in Patients With Frequent Heartburn

    NCT01370538 · start 2011-08

    Registered record
    Registry ID
    NCT01370538
    Conditions
    Heartburn
    Interventions
    Esomeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-08
    Completion
    2011-10
    Enrolment
    341

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeartburn
    InterventionEsomeprazole
    PhasePhase 3
    Registry statusCompleted

  • Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Esomeprazole Magnesium DR Capsules Under Fasting Conditions

    NCT02659683 · start 2011-05

    Registered record
    Registry ID
    NCT02659683
    Conditions
    Healthy Subjects
    Interventions
    Nexium 40 mg DR Capsules of AstraZeneca LP, USA; Torrent's Esomeprazole Magnesium DR Capsules 40 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-05
    Completion
    2011-05
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionNexium 40 mg DR Capsules of AstraZeneca LP, USA; Torrent's Esomeprazole Magnesium DR Capsules 40 mg
    PhasePhase 1
    Registry statusCompleted

  • BE of Torrent's Esomeprazole Mg DR Capsules

    NCT02680119 · start 2011-05

    Registered record
    Registry ID
    NCT02680119
    Conditions
    Healthy
    Interventions
    Nexium 40 mg DR Capsules of AstraZeneca LP, USA.; Torrent's Esomeprazole Magnesium DR Capsules 40 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-05
    Completion
    2011-05
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionNexium 40 mg DR Capsules of AstraZeneca LP, USA.; Torrent's Esomeprazole Magnesium DR Capsules 40 mg
    PhasePhase 1
    Registry statusCompleted

  • Bioequivalence Study of Torrent Pharmaceutical Ltd's Esomeprazole Magnesium Delayed Release Capsules

    NCT02680132 · start 2011-05

    Registered record
    Registry ID
    NCT02680132
    Conditions
    Healthy
    Interventions
    Nexium 40 mg DR Capsules of AstraZeneca LP, USA; Torrent's Esomeprazole Magnesium DR Capsules 40 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-05
    Completion
    2011-05
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionNexium 40 mg DR Capsules of AstraZeneca LP, USA; Torrent's Esomeprazole Magnesium DR Capsules 40 mg
    PhasePhase 1
    Registry statusCompleted

  • Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers

    NCT01135472 · start 2010-03

    Registered record
    Registry ID
    NCT01135472
    Conditions
    Healthy
    Interventions
    Esomeprazole Magnesium
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-03
    Completion
    2012-04
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionEsomeprazole Magnesium
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

    NCT00978016 · start 2009-09

    Registered record
    Registry ID
    NCT00978016
    Conditions
    Gastroesophageal Reflux Disease
    Interventions
    arbaclofen placarbil-Cohort 1; Placebo-Cohort 5; arbaclofen placarbil-Cohort 2; arbaclofen placarbil-Cohort 3; arbaclofen placarbil-Cohort 4; PPI
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-09
    Completion
    2010-12
    Enrolment
    460

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroesophageal Reflux Disease
    Interventionarbaclofen placarbil-Cohort 1; Placebo-Cohort 5; arbaclofen placarbil-Cohort 2; arbaclofen placarbil-Cohort 3 +2 more
    PhasePhase 2
    Registry statusCompleted

  • Viokase 16, Viokase16 Plus Nexium and Nexium Alone

    NCT01142128 · start 2009-02

    Registered record
    Registry ID
    NCT01142128
    Conditions
    Chronic Pancreatitis
    Interventions
    Nexium (esomeprazole magnesium); Placebo to Nexium; Viokase 16 (pancrelipase) + Nexium; Viokase 16 + placebo to Nexium
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2009-02
    Completion
    2012-03
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Pancreatitis
    InterventionNexium (esomeprazole magnesium); Placebo to Nexium; Viokase 16 (pancrelipase) + Nexium; Viokase 16 + placebo to Nexium
    PhasePhase 1
    Registry statusTerminated